Broadcom
AVGO
Taiwan Semiconductor
TSM
Tesla
TSLA
ASML Holding
ASML
Qualcomm
QCOM
US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 0.700
- -0.024-3.31%
Close Dec 13 16:00 ET
- 0.707
- +0.007+1.00%
Post 19:52 ET
87.72MMarket Cap-0.67P/E (TTM)
0.735High0.692Low1.44MVolume0.710Open0.724Pre Close1.03MTurnover1.27%Turnover RatioLossP/E (Static)125.31MShares1.95052wk High-0.55P/B79.71MFloat Cap0.65552wk Low--Dividend TTM113.87MShs Float49.005Historical High--Div YieldTTM5.93%Amplitude0.617Historical Low0.711Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Karyopharm Therapeutics Stock Forum
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
No comment yet